CTOs on the Move


 
TherOx, Inc. (TherOx) is a private, venture-financed medical device company based in Irvine, California, dedicated to elevating the standard of care for treatment of heart attack patients. A heart attack is caused when an artery in the heart becomes blocked. Current treatment of heart attack is to reestablish blood flow in the blocked artery as quickly as possible. Typically, this is done with a combination of medication and a percutaneous coronary intervention (PCI) which may include the placement of a (intracoronary) stent. PCI successfully restores blood flow, but damage to the patient’s heart remains. Blood flow in the microvasculature downstream from the ...
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.therox.com
  • 17500 Cartwright Rd Ste 100
    Irvine, CA USA 92614
  • Phone: 949.757.1999

Executives

Name Title Contact Details

Funding

TherOx raised $16.8M on 08/10/2015

Similar Companies

WHC

WHC is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The Institute for Family Health

The Institute for Family Health is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. The Institute for Family Health is based in New York, NY. You can find more information on The Institute for Family Health at www.institute2000.org

CONFIDENT SMILE

CONFIDENT SMILE is a Lancaster, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Health-E-Quip

Health-E-Quip is a Hutchinson, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bioatla

BioAtla was founded in 2007 and employs deep expertise in protein engineering to develop better monoclonal antibody and other protein therapeutics. Our suite of proprietary technologies (protected by more than 70 issued patents and patent applications) has enabled us to develop dozens of novel therapeutic proteins for our partners and our own pipeline. We accelerate the process from target discovery to manufacturing and preclinical studies by creating drugs with more selective targeting, greater affinity, and more cost-efficient and predictable manufacturing. In the process we also create valuable, protectable IP that gives our partners significant competitive advantage. The culmination of our protein evolution technologies is our Conditionally Active Biologics (CAB)platform. Monoclonal antibodies or enzymes can be engineered for selective conditional activation, i.e. the protein`s functions are designed to modulate with changes in microphysical conditions (e.g., pH level, oxidation, temperature, pressure concentration, presence of certain ions, hydrophobicity and competing protein binding). Tumors and other kinds of diseased tissue give rise to unique localized conditions distinct from normal tissue. CAB designed monoclonal antibodies can be programmed to deliver an ADC payload and/or recruit the immune response to specific sites and conditions in the body.